Murine Rankl-/- Mesenchymal Stromal Cells Display an Osteogenic Differentiation Defect Improved by a RANKL-Expressing Lentiviral Vector

Francesca Schena, Ciro Menale, Emanuela Caci, Lorenzo Diomede, Eleonora Palagano, Camilla Recordati, Monica Sandri, Anna Tampieri, Ileana Bortolomai, Valentina Capo, Claudia Pastorino, Arinna Bertoni, Marco Gattorno, Alberto Martini, Anna Villa, Elisabetta Traggiai, Cristina Sobacchi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Autosomal recessive osteopetrosis (ARO) is a severe bone disease characterized by increased bone density due to impairment in osteoclast resorptive function or differentiation. Hematopoietic stem cell transplantation is the only available treatment; however, this therapy is not effective in RANKL-dependent ARO, since in bone this gene is mainly expressed by cells of mesenchymal origin. Of note, whether lack of RANKL production might cause a defect also in the bone marrow (BM) stromal compartment, possibly contributing to the pathology, is unknown. To verify this possibility, we generated and characterized BM mesenchymal stromal cell (BM-MSC) lines from wild type and Rankl-/- mice, and found that Rankl-/- BM-MSCs displayed reduced clonogenicity and osteogenic capacity. The differentiation defect was significantly improved by lentiviral transduction of Rankl-/- BM-MSCs with a vector stably expressing human soluble RANKL (hsRANKL). Expression of Rankl receptor, Rank, on the cytoplasmic membrane of BM-MSCs pointed to the existence of an autocrine loop possibly activated by the secreted cytokine. Based on the close resemblance of RANKL-defective osteopetrosis in humans and mice, we expect that our results are also relevant for RANKL-dependent ARO patients. Data obtained in vitro after transduction with a lentiviral vector expressing hsRANKL would suggest that restoration of RANKL production might not only rescue the defective osteoclastogenesis of this ARO form, but also improve a less obvious defect in the osteoblast lineage, thus possibly achieving higher benefit for the patients, when the approach is translated to clinics. Stem Cells 2017;35:1365-1377.
Original languageEnglish
Pages (from-to)1365-1377
Number of pages13
JournalStem Cells
Volume35
Issue number5
DOIs
Publication statusPublished - May 2017

Fingerprint

Osteopetrosis
Mesenchymal Stromal Cells
Bone Marrow
Bone Diseases
Hematopoietic Stem Cell Transplantation
Osteoclasts
Osteoblasts
Osteogenesis
Bone Density
Stem Cells
Cell Membrane
Pathology
Cytokines
Bone and Bones
Cell Line
Therapeutics
Genes

Keywords

  • Animals
  • Biomarkers
  • Cell Differentiation
  • Clone Cells
  • Genetic Vectors
  • Immunophenotyping
  • Lentivirus
  • Mesenchymal Stromal Cells
  • Mice, Inbred C57BL
  • Osteogenesis
  • RANK Ligand
  • Signal Transduction
  • Transduction, Genetic
  • Journal Article

Cite this

Murine Rankl-/- Mesenchymal Stromal Cells Display an Osteogenic Differentiation Defect Improved by a RANKL-Expressing Lentiviral Vector. / Schena, Francesca; Menale, Ciro; Caci, Emanuela; Diomede, Lorenzo; Palagano, Eleonora; Recordati, Camilla; Sandri, Monica; Tampieri, Anna; Bortolomai, Ileana; Capo, Valentina; Pastorino, Claudia; Bertoni, Arinna; Gattorno, Marco; Martini, Alberto; Villa, Anna; Traggiai, Elisabetta; Sobacchi, Cristina.

In: Stem Cells, Vol. 35, No. 5, 05.2017, p. 1365-1377.

Research output: Contribution to journalArticle

Schena, F, Menale, C, Caci, E, Diomede, L, Palagano, E, Recordati, C, Sandri, M, Tampieri, A, Bortolomai, I, Capo, V, Pastorino, C, Bertoni, A, Gattorno, M, Martini, A, Villa, A, Traggiai, E & Sobacchi, C 2017, 'Murine Rankl-/- Mesenchymal Stromal Cells Display an Osteogenic Differentiation Defect Improved by a RANKL-Expressing Lentiviral Vector', Stem Cells, vol. 35, no. 5, pp. 1365-1377. https://doi.org/10.1002/stem.2574
Schena, Francesca ; Menale, Ciro ; Caci, Emanuela ; Diomede, Lorenzo ; Palagano, Eleonora ; Recordati, Camilla ; Sandri, Monica ; Tampieri, Anna ; Bortolomai, Ileana ; Capo, Valentina ; Pastorino, Claudia ; Bertoni, Arinna ; Gattorno, Marco ; Martini, Alberto ; Villa, Anna ; Traggiai, Elisabetta ; Sobacchi, Cristina. / Murine Rankl-/- Mesenchymal Stromal Cells Display an Osteogenic Differentiation Defect Improved by a RANKL-Expressing Lentiviral Vector. In: Stem Cells. 2017 ; Vol. 35, No. 5. pp. 1365-1377.
@article{8d209d54716541c6b33e2dd8441c2a9b,
title = "Murine Rankl-/- Mesenchymal Stromal Cells Display an Osteogenic Differentiation Defect Improved by a RANKL-Expressing Lentiviral Vector",
abstract = "Autosomal recessive osteopetrosis (ARO) is a severe bone disease characterized by increased bone density due to impairment in osteoclast resorptive function or differentiation. Hematopoietic stem cell transplantation is the only available treatment; however, this therapy is not effective in RANKL-dependent ARO, since in bone this gene is mainly expressed by cells of mesenchymal origin. Of note, whether lack of RANKL production might cause a defect also in the bone marrow (BM) stromal compartment, possibly contributing to the pathology, is unknown. To verify this possibility, we generated and characterized BM mesenchymal stromal cell (BM-MSC) lines from wild type and Rankl-/- mice, and found that Rankl-/- BM-MSCs displayed reduced clonogenicity and osteogenic capacity. The differentiation defect was significantly improved by lentiviral transduction of Rankl-/- BM-MSCs with a vector stably expressing human soluble RANKL (hsRANKL). Expression of Rankl receptor, Rank, on the cytoplasmic membrane of BM-MSCs pointed to the existence of an autocrine loop possibly activated by the secreted cytokine. Based on the close resemblance of RANKL-defective osteopetrosis in humans and mice, we expect that our results are also relevant for RANKL-dependent ARO patients. Data obtained in vitro after transduction with a lentiviral vector expressing hsRANKL would suggest that restoration of RANKL production might not only rescue the defective osteoclastogenesis of this ARO form, but also improve a less obvious defect in the osteoblast lineage, thus possibly achieving higher benefit for the patients, when the approach is translated to clinics. Stem Cells 2017;35:1365-1377.",
keywords = "Animals, Biomarkers, Cell Differentiation, Clone Cells, Genetic Vectors, Immunophenotyping, Lentivirus, Mesenchymal Stromal Cells, Mice, Inbred C57BL, Osteogenesis, RANK Ligand, Signal Transduction, Transduction, Genetic, Journal Article",
author = "Francesca Schena and Ciro Menale and Emanuela Caci and Lorenzo Diomede and Eleonora Palagano and Camilla Recordati and Monica Sandri and Anna Tampieri and Ileana Bortolomai and Valentina Capo and Claudia Pastorino and Arinna Bertoni and Marco Gattorno and Alberto Martini and Anna Villa and Elisabetta Traggiai and Cristina Sobacchi",
note = "{\circledC} 2017 AlphaMed Press.",
year = "2017",
month = "5",
doi = "10.1002/stem.2574",
language = "English",
volume = "35",
pages = "1365--1377",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - Murine Rankl-/- Mesenchymal Stromal Cells Display an Osteogenic Differentiation Defect Improved by a RANKL-Expressing Lentiviral Vector

AU - Schena, Francesca

AU - Menale, Ciro

AU - Caci, Emanuela

AU - Diomede, Lorenzo

AU - Palagano, Eleonora

AU - Recordati, Camilla

AU - Sandri, Monica

AU - Tampieri, Anna

AU - Bortolomai, Ileana

AU - Capo, Valentina

AU - Pastorino, Claudia

AU - Bertoni, Arinna

AU - Gattorno, Marco

AU - Martini, Alberto

AU - Villa, Anna

AU - Traggiai, Elisabetta

AU - Sobacchi, Cristina

N1 - © 2017 AlphaMed Press.

PY - 2017/5

Y1 - 2017/5

N2 - Autosomal recessive osteopetrosis (ARO) is a severe bone disease characterized by increased bone density due to impairment in osteoclast resorptive function or differentiation. Hematopoietic stem cell transplantation is the only available treatment; however, this therapy is not effective in RANKL-dependent ARO, since in bone this gene is mainly expressed by cells of mesenchymal origin. Of note, whether lack of RANKL production might cause a defect also in the bone marrow (BM) stromal compartment, possibly contributing to the pathology, is unknown. To verify this possibility, we generated and characterized BM mesenchymal stromal cell (BM-MSC) lines from wild type and Rankl-/- mice, and found that Rankl-/- BM-MSCs displayed reduced clonogenicity and osteogenic capacity. The differentiation defect was significantly improved by lentiviral transduction of Rankl-/- BM-MSCs with a vector stably expressing human soluble RANKL (hsRANKL). Expression of Rankl receptor, Rank, on the cytoplasmic membrane of BM-MSCs pointed to the existence of an autocrine loop possibly activated by the secreted cytokine. Based on the close resemblance of RANKL-defective osteopetrosis in humans and mice, we expect that our results are also relevant for RANKL-dependent ARO patients. Data obtained in vitro after transduction with a lentiviral vector expressing hsRANKL would suggest that restoration of RANKL production might not only rescue the defective osteoclastogenesis of this ARO form, but also improve a less obvious defect in the osteoblast lineage, thus possibly achieving higher benefit for the patients, when the approach is translated to clinics. Stem Cells 2017;35:1365-1377.

AB - Autosomal recessive osteopetrosis (ARO) is a severe bone disease characterized by increased bone density due to impairment in osteoclast resorptive function or differentiation. Hematopoietic stem cell transplantation is the only available treatment; however, this therapy is not effective in RANKL-dependent ARO, since in bone this gene is mainly expressed by cells of mesenchymal origin. Of note, whether lack of RANKL production might cause a defect also in the bone marrow (BM) stromal compartment, possibly contributing to the pathology, is unknown. To verify this possibility, we generated and characterized BM mesenchymal stromal cell (BM-MSC) lines from wild type and Rankl-/- mice, and found that Rankl-/- BM-MSCs displayed reduced clonogenicity and osteogenic capacity. The differentiation defect was significantly improved by lentiviral transduction of Rankl-/- BM-MSCs with a vector stably expressing human soluble RANKL (hsRANKL). Expression of Rankl receptor, Rank, on the cytoplasmic membrane of BM-MSCs pointed to the existence of an autocrine loop possibly activated by the secreted cytokine. Based on the close resemblance of RANKL-defective osteopetrosis in humans and mice, we expect that our results are also relevant for RANKL-dependent ARO patients. Data obtained in vitro after transduction with a lentiviral vector expressing hsRANKL would suggest that restoration of RANKL production might not only rescue the defective osteoclastogenesis of this ARO form, but also improve a less obvious defect in the osteoblast lineage, thus possibly achieving higher benefit for the patients, when the approach is translated to clinics. Stem Cells 2017;35:1365-1377.

KW - Animals

KW - Biomarkers

KW - Cell Differentiation

KW - Clone Cells

KW - Genetic Vectors

KW - Immunophenotyping

KW - Lentivirus

KW - Mesenchymal Stromal Cells

KW - Mice, Inbred C57BL

KW - Osteogenesis

KW - RANK Ligand

KW - Signal Transduction

KW - Transduction, Genetic

KW - Journal Article

U2 - 10.1002/stem.2574

DO - 10.1002/stem.2574

M3 - Article

VL - 35

SP - 1365

EP - 1377

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 5

ER -